drugset / Trial / NCT01125748
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
RandomizedParallel-groupDouble-blindTreatment
Summary
This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatment with Xolair were allowed to enter the study.
Timeline
- Start
- 2010-05
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | — | Subcutaneous |
| Background | Prednisone | Other / unclassified | — | Oral |
| Background | Zafirlukast | Small molecule | — | — |
| Background | Zileuton | Small molecule | — | — |